Bioneer

Bioneer Current Assets

The Current Assets of Bioneer (064550.KQ) as of Nov 13, 2026 is 37.74 B KRW. In the previous year, Current Assets was 52.76 B KRW — a change of -28.48% (lower).

Current Assets

37.74 BKRW

YoY

-28.48%

Last updated:

Current Assets of Bioneer is 2025 37.74 B KRW. Current Assets of Bioneer was 2024 52.76 B KRW. It decreases by -28.48% lower compared to the previous year.

The Bioneer Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
31.14 B KRW
Jan 1, 2019
43.61 B KRW
Jan 1, 2020
94.72 B KRW
Jan 1, 2021
131.84 B KRW
Jan 1, 2022
132.19 B KRW
Jan 1, 2023
53.94 B KRW
Jan 1, 2024
52.76 B KRW
Jan 1, 2025
37.74 B KRW
The Bioneer Current Assets history
YEARCurrent AssetsYoY
37.74 BKRW-28.48%
52.76 BKRW-2.18%
53.94 BKRW-59.19%
132.19 BKRW+0.26%
131.84 BKRW+39.20%
94.72 BKRW+117.20%
43.61 BKRW+40.02%
31.14 BKRW+15.23%
27.03 BKRW+22.98%
21.98 BKRW-26.96%
30.09 BKRW+22.44%
24.57 BKRW-8.27%
26.79 BKRW+15.57%
23.18 BKRW+1.90%
22.75 BKRW-0.54%
22.87 BKRW-27.97%
31.75 BKRW+71.09%
18.56 BKRW+18.66%
15.64 BKRW-11.06%
17.58 BKRW-39.93%
29.27 BKRW+220.61%
9.13 BKRW-12.59%
10.44 BKRW-14.83%
12.26 BKRW+1.34%
12.10 BKRW-70.87%
41.54 BKRW+2,084.23%
1.90 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioneer Stock analysis

What does Bioneer do? BIONEER Corp. generates revenue through the sale of biotechnological products, primarily DNA reagents, molecular diagnostic kits, and related services. The company offers DNA and RNA amplification products, Oligo synthesis, gene synthesis services, gene and protein expression, genomics services, and human and veterinary diagnostics kits. It also sells DNA extraction, amplification, and quantitative analysis devices, along with equipment and supplies for biotechnology research. These products are sold to domestic and international markets, including America, China, Japan, India, and Africa, where they serve research institutions, diagnostic laboratories, and healthcare providers. The firm's revenue streams include DNA reagents, molecular diagnostic kits, and DNA diagnostic devices, which are used by customers in the biotechnology, healthcare, and veterinary sectors. DNA amplification products and gene synthesis services are key offerings for research-focused clients, while human and veterinary diagnostics kits target healthcare and animal health markets. Equipment and supplies for biotechnology research are sold to academic and commercial laboratories globally. BIONEER Corp. focuses on developing and selling specialized biotechnology products, with a strong emphasis on DNA and RNA-related technologies. Its product portfolio includes reagents, kits, devices, and services that cater to both research and diagnostic applications. The company's international presence in key markets like America, China, and Japan drives its revenue, with a significant portion coming from the sale of diagnostic kits and DNA analysis equipment. Bioneer is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioneer stock

Current Assets of Bioneer is 37.74 B KRW in 2025.

Current Assets of Bioneer changed from 52.76 B KRW to 37.74 B KRW, representing a -28.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Bioneer since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Bioneer historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bioneer

All Key Metrics — Bioneer